Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Fig. 2

Images a, b, and c: Contrast-enhanced T1-weighted magnetic ressonance imaging (MRI) acquired prior to initiation of treatment (September, 2016), demonstrating lesion with heterogeneous enhancement (arrows) in the right cavernous sinus with insinuation in the superior orbital fissure measuring 24 × 21 × 19 mm. Images d, e and +: Brain MRI one year after the initiation of Vemurafenib (September 2017) showing significant reduction of lesion dimensions, measuring 18 × 13 × 14 mm

Back to article page